VCA Stocks

Fovea Pharmaceuticals SA has raised EUR 30 million ($43.5 mm) in Series B funding.  Fovea Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovation in products for ocular diseases (retinal degeneration, macular edema, glaucoma, and inflammation).  Treatments for:  Back of the eye diseases, Age related macular degeneration, Retinal degeneration, Dry AMD, Wet AMD, Retinitis pigmentosa, Glaucoma, Diabetic retinopathy, Stargard’s disease, Retinal vascular diseases, Diabetic retinopathy, Ganglion cells degenaration